Management of hepatitis C in patients with chronic kidney disease

被引:0
作者
Roberto J Carvalho-Filho [1 ]
Ana Cristina CA Feldner [1 ]
Antonio Eduardo B Silva [1 ]
Maria Lucia G Ferraz [1 ]
机构
[1] Division of Gastroenterology,Hepatology Section,Federal University of Sao Paulo,Sao Paulo,SP 04023-900,Brazil
关键词
Hepatitis C virus; Chronic kidney disease; End-stage renal disease; Hemodialysis; Kidney transplantation; Diagnosis; Conservative management; Therapy;
D O I
暂无
中图分类号
R692 [肾疾病]; R512.63 [];
学科分类号
1002 ; 100210 ; 100401 ;
摘要
Hepatitis C virus(HCV) infection is highly prevalent among chronic kidney disease(CKD) subjects under hemodialysis and in kidney transplantation(KT) recipients, being an important cause of morbidity and mortality in these patients. The vast majority of HCV chronic infections in the hemodialysis setting are currently attributable to nosocomial transmission. Acute and chronic hepatitis C exhibits distinct clinical and laboratorial features, which can impact on managementand treatment decisions. In hemodialysis subjects, acute infections are usually asymptomatic and anicteric; since spontaneous viral clearance is very uncommon in this context, acute infections should be treated as soon as possible. In KT recipients, the occurrence of acute hepatitis C can have a more severe course, with a rapid progression of liver fibrosis. In these patients, it is recommended to use pegylated interferon(PEG-IFN) in combination with ribavirin, with doses adjusted according to estimated glomerular filtration rate. There is no evidence suggesting that chronic hepatitis C exhibits a more aggressive course in CKD subjects under conservative management. In these subjects, indication of treatment with PEG-IFN plus ribavirin relies on the CKD stage, rate of progression of renal dysfunction and the possibility of a preemptive transplant. HCV infection has been associated with both liver disease-related deaths and cardiovascular mortality in hemodialysis patients. Among those individuals, low HCV viral loads and the phenomenon of intermittent HCV viremia are often observed, and sequential HCV RNA monitoring is needed. Despite the poor tolerability and suboptimal efficacy of antiviral therapy in CKD patients, many patients can achieve sustained virological response, which improve patient and graft outcomes. Hepatitis C eradication before KT theoretically improves survival and reduces the occurrence of chronic graft nephropathy, de novo glomerulonephritis and post-transplant diabetes mellitus.
引用
收藏
页码:408 / 422
页数:15
相关论文
共 88 条
[1]  
Efficacy and safety of treatment of hepatitis C virus infection in renal transplant recipients[J]. Abdulrahman A Aljumah,Mohamed A Saeed,Ahmed I Al Flaiw,Ibrahim H Al Traif,Abduljaleel M Al Alwan,Salem H Al Qurashi,Ghormallah A Al Ghamdi,Fayez F Al Hejaili,Mohammed A Al Balwi,Abdulla A Al Sayyari.World Journal of Gastroenterology. 2012(01)
[2]   Natural history of chronic hepatitis C in patients on hemodialysis: Case control study with 4-23 years of follow-up [J].
Kunio Okuda ;
Osamu Yokosuka .
World Journal of Gastroenterology, 2004, (15) :2209-2212
[3]   A case of sustained virologic response of HCV with telaprevir-based therapy in a patient with HIV and end stage kidney disease [J].
Slim, J. ;
Scangarello, N. ;
Samaha, P. ;
Dazley, J. .
INTERNATIONAL JOURNAL OF STD & AIDS, 2014, 25 (11) :830-832
[4]  
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial[J] . Ira M Jacobson,Gregory J Dore,Graham R Foster,Michael W Fried,Monica Radu,Vladimir V Rafalsky,Larysa Moroz,Antonio Craxi,Monika Peeters,Oliver Lenz,Sivi Ouwerkerk-Mahadevan,Guy De La Rosa,Ronald Kalmeijer,Jane Scott,Rekha Sinha,Maria Beumont-Mauviel.The Lancet . 2014 (9941)
[5]  
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study[J] . Eric Lawitz,Mark S Sulkowski,Reem Ghalib,Maribel Rodriguez-Torres,Zobair M Younossi,Ana Corregidor,Edwin DeJesus,Brian Pearlman,Mordechai Rabinovitz,Norman Gitlin,Joseph K Lim,Paul J Pockros,John D Scott,Bart Fevery,Tom Lambrecht,Sivi Ouwerkerk-Mahadevan,Katleen Ca
[6]   LETTER [J].
ZHAO Hong .
China Textile, 2014, (11) :1-1
[7]  
Telaprevir pharmacokinetics in a hepatitis C virus infected patient on haemodialysis[J] . Clara TMM de Kanter,Jan G den Hollander,Corrien P.W.G.M. Verweij-van Wissen,David M. Burger.Journal of Clinical Virology . 2014
[8]  
Meta‐analysis of observational studies: hepatitis C and survival after renal transplant[J] . F. Fabrizi,P. Martin,V. Dixit,P. Messa.J Viral Hepat . 2014 (5)
[9]   Antiviral triple therapy with boceprevir in a chronic hepatitis C haemodialysis patient awaiting kidney re-transplantation [J].
Knapstein, Johanna ;
Galle, Peter R. ;
Zimmermann, Tim .
DIGESTIVE AND LIVER DISEASE, 2014, 46 (01) :88-89
[10]  
Prevalence of occult hepatitis C infection in chronic hemodialysis and kidney transplant patients[J] . Seema Baid-Agrawal,Ralf Schindler,Petra Reinke,Adrienne Staedtler,Sunda Rimpler,Barbara Malik,Ulrich Frei,Thomas Berg.Journal of Hepatology . 2014